Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1212/NXI.0000000000000213

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320290

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia

ABSTRACT

Objective: To describe the compassionate use of interleukin-7 (IL-7) for treatment of progressive multifocal leukoencephalopathy (PML) in the setting of idiopathic CD8+ greater than CD4+ lymphocytopenia.

Methods: A 66-year-old HIV-seronegative man presented with progressive language dysfunction. MRI showed hyperintense lesions in the left hemispheric white matter with mild contrast enhancement. A brain biopsy performed 4 months after symptom onset established the diagnosis of PML. The patient had profound lymphocytopenia with absolute lymphocyte count (ALC) at 168 cells/μL, 87 CD4+ T cells/μL, and 7 CD8+ T cells/μL. There was no evidence of hematologic malignancy or rheumatologic disease.

Results: The patient received 3 intramuscular injections of IL-7 at a dose of 10 μg/kg per week with no adverse effects. ALC peaked at 595 cells/μL, CD4+ T cells at 301 cells/μL, and CD8+ T cells at 34 cells/μL 3 weeks after completion of treatment. His lesions on MRI stabilized and neurologic examination mildly improved. JCV-specific T-cell responses measured by intracellular cytokine staining were not altered after treatment with IL-7 but there was a marked increase in regulatory T cells.

Conclusion: This case further supports the investigational use of IL-7 in patients who develop PML in the setting of ICL.

Classification of evidence: This study provides Class IV evidence that for patients with ICL and PML, IL-7 improves PML-related-outcomes. The study is rated Class IV because it is a case report. Neurology Neuroimmunol Neuroinflamm 2016;3:e213; doi: 10.1212/NXI.0000000000000213

GLOSSARY

IL-7 = interleukin-7; IRIS = immune reconstitution inflammatory syndrome; JCV = JC polyomavirus; Lip1/Cr = lipid 1/creatine; MRS = magnetic resonance spectroscopy; NIHSS = NIH Stroke Scale; PML = progressive multifocal leukoencephalopathy; TReg = regulatory T cell.

Progressive multifocal leukoencephalopathy (PML), caused by the JC polyomavirus (JCV), is a demyelinating disorder for which there is no cure.1 Upon review of the literature, 12 previous cases of PML in the setting of idiopathic CD4+ lymphocytopenia (ICL) have been reported.2 ICL is diagnosed when absolute CD4+ T-cell counts are less than 300 cells/μL on more than one occasion in the absence of other causes of immunocompromised state.3 Several medications have been utilized for treatment of PML in patients with ICL, but none has proven efficacious.4 However, recovery of anti-JCV T-cell responses correlates with PML survival.5 Interleukin-7 (IL-7) is a multifunctional cytokine that is essential for T-cell proliferation, modulation of peripheral T-cell subsets, and enhancement of T-cell functionality, including virus-specific immunity.6 Recently, IL-7 has been used in Europe for treatment of PML in the setting of ICL and secondary lymphocytopenia with normal CD8+ T-cell counts.7–9 We
report the case of a patient with lymphocytopenia affecting CD8+ more than CD4+ T cells as well as B cells who developed PML and was treated with IL-7. We studied radiologic markers of disease evolution using magnetic resonance spectroscopy (MRS) and perfusion MRI and monitored his immune response to JCV using intracellular cytokine staining.

**CASE REPORT** A 66-year-old man with a history of hypertension and hypercholesterolemia began to notice subtle problems with language. One month later, an outpatient brain MRI was interpreted as subacute left temporo-parietal stroke, leading to his hospitalization at our institution. Complete blood count (CBC) on admission showed 6,700 leukocytes with 5.9% lymphocytes corresponding to an absolute lymphocyte count (ALC) of 395 cells/µL. He was discharged on antiplatelet and statin therapies, but his symptoms progressed over the next 2 months as he developed worsening word-finding difficulties, paraphasic errors, and trouble reading and writing. A repeat brain MRI was interpreted as increased edema in the left hemisphere with possible cortical enhancement. He was again hospitalized and CSF examination showed 3 leukocytes, 1,045 erythrocytes, protein 36 mg/dL, and glucose 77 mg/dL. Herpes simplex virus 1 and 2 DNA was not detected via PCR. MRS revealed an elevated choline peak in the left parietal white matter suggestive of malignancy. CBC on admission showed 4,700 leukocytes with 7% lymphocytes corresponding to an ALC of 329 cells/µL.

The patient underwent elective stereotactic brain biopsy of the left temporo-parietal brain lesion 1 month later, for presumptive diagnosis of glioma. Histopathologic examination revealed marked reactive gliosis, scattered bizarre astrocytes with enlarged nuclei, and numerous SV40-positive nuclear inclusions, consistent with the diagnosis of PML. There was infiltration by CD3+ T and CD20+ B lymphocytes, as well as numerous CD68+ macrophages. He was subsequently evaluated in our Neuroinfectious Diseases Clinic, at which time his neurologic examination showed a mixed expressive greater than receptive aphasia (NIH Stroke Scale [NIHSS] score = 1). Brain MRI 1 month after biopsy showed mildly enhancing left hemispheric PML lesions and MRS revealed a lipid 1/creatine (Lip1/Cr) ratio >1.5 in the left temporo-parietal lesion indicating a 79% likelihood of immune reconstitution inflammatory syndrome (IRIS). Arterial spin labeling MRI showed no evidence of hyperperfusion around the PML lesions, consistent with a favorable outcome. Serologic tests were negative for HIV-1, HIV-2, hepatitis, antinuclear antibodies, dsDNA, ribosomal P antibody, and Sjögren antibodies. The erythrocyte sedimentation rate, angiotensin-converting enzyme, rheumatoid factor, and complement levels were within normal limits. Immunoglobulin (Ig) studies were normal (IgG total 1,331 mg/dL, IgA 196 mg/dL, and IgM 166 mg/dL). Initial T-cell subsets revealed profound lymphocytopenia (ALC 168 cells/µL, CD4+ count 87 cells/µL, CD8+ count 7 cells/µL, CD4/CD8 ratio 12.4, and CD19+/CD20+ counts 4–8 cells/µL). Based upon the absence of history of recurrent infections, inflammatory or autoimmune disorders, malignancy, recent surgery, or bone marrow suppressing medications, the most likely diagnosis was believed to be idiopathic lymphocytopenia. Retrospective review of past records indicated that this patient already had a low ALC 8 years (590 cells/µL) and 4 years (310 cells/µL) prior to the onset of PML symptoms. JCV DNA
in CSF was not detected by PCR, but quantitative PCR in DNA extracted from paraffin sections of brain tissue showed 5.2 million JCV copies/slide. This confirmed the diagnosis of PML in the setting of idiopathic lymphocytopenia involving CD8+ more than CD4+ T cells.

**METHODS** Standard protocol approvals, registrations, and patient consents. We obtained an emergency investigational new drug approval from the Food and Drug Administration for the compassionate use of IL-7 (CYT107, RevImmune, Paris, France). Single-patient use institutional review board approval was obtained from the Beth Israel Deaconess Medical Center (BIDMC) Committee on Clinical Investigations. A Materials Transfer Agreement between RevImmune and BIDMC was negotiated. Written informed consent was obtained from the patient. CYT107 was dispensed by the BIDMC research pharmacy and administered in the BIDMC Infusion Center. We used the NIHSS to assess for changes in neurologic status.

**RESULTS** A single cycle of IL-7 was administered intramuscularly once weekly for 3 consecutive weeks at a dose of 10 µg/kg with no adverse effects. The patient’s neurologic examination showed a stable moderate mixed aphasia (NIHSS = 1) with no new neurologic deficits compared to a pre-IL-7 examination. Brain MRI 2 weeks post IL-7 showed less conspicuous but persistently enhancing left hemispheric PML lesions, and a new, small, enhancing left cerebellar lesion (figure 1). MRS was unchanged in the left temporo-parietal region, and the new left cerebellar enhancing lesion had a Lip1/Cr ratio ≤1.5. CSF JCV DNA was again undetectable by PCR 3 weeks post IL-7. From the first measurement of T-cell subsets 2 months pre-IL-7 to repeat T-cell subsets 3 weeks post IL-7, there was an increase in ALC from 168 to 595 cells/µL, CD4+ T cells from 87 to 301 cells/µL, and CD8+ T cells from 7 to 34 cells/µL (figure 2). Twenty-nine weeks after IL-7 therapy, there was a decline in ALC to 242 cells/µL, CD4+ T cells to 87 cells/µL, and CD8+ T cells to 4 cells/µL, back to pre-IL-7 baseline levels. Over 6 months, the B cells remained stably low, ranging from 4 to 41 cells/µL. The leukocyte count fluctuated significantly throughout IL-7 treatment, but always remained in the normal range (4.5–9.4 K/µL). JCV-specific CD4+ and CD8+ T-cell responses were measured by intracellular cytokine staining 1 week pre-IL-7, and they were unaltered 1 week post-IL-7 treatment. Interestingly, IL-7 induced a 10-fold increase in the overall percentage of regulatory T cells (TReg) (figure 3). While recent studies have shown that IL-2 is the main factor driving the development of TReg, IL-7 can also mediate intrathymic TReg development. On the

![Figure 2](image-url)
patient’s most recent MRI 16 weeks after treatment, the PML lesions remained unchanged except for the disappearance of contrast enhancement. There was also a decrease in the Lip1/Gr ratio <1.5, indicating resolution of IRIS. The patient was started on trimethoprim/sulfamethoxazole for prevention of other opportunistic infections. On his 7-month follow-up post IL-7 administration, 13 months after onset of PML, his neurologic examination showed mild improvement in speed and fluency of speech (NIHSS = 1).

**DISCUSSION**

Effective treatments for PML do not exist, and standard therapies to increase CD4+ and CD8+ T cells or improve immune function in ICL are not commercially available. One of the key drivers of T-cell homeostasis and function is IL-7, and preliminary data indicate that this cytokine may augment virus-specific immune responses, which could provide clinical benefit for immunosuppressed individuals, including those with ICL.6 Due to the often fatal outcome of PML, our patient was treated with intramuscular injections of IL-7 with the aim to restore overall immune function. Uniquely, our patient had multiple lymphocytopenias with low CD8+ T cells, CD4+ T cells, and B cells. The effects of IL-7 were selective with regard to T-cell subsets as the CD4+ T-cell population expanded to a greater extent than CD8+ T cells. This is relevant since CD8+ T cells are thought to be most important in containing JC virus. As expected, there was no effect on B-cell counts. Of note, treatment with IL-7 was well-tolerated, with no IRIS during 7 months of follow-up. CD4+ T-cell counts remained elevated for approximately 3 months after treatment with IL-7. Given that the half-life of IL-7 is 7–23 hours, our results suggest that the biological effects of IL-7 on blood cell counts continue after serum cytokine levels return to baseline, usually 72 hours after injection.5 Thus, in the present case, investigational use of IL-7 led to rapid increase in overall CD4+ T-cell counts and was associated with clinical benefit. Since the patient remains alive more than 1 year from PML onset, he is considered a PML survivor, and is expected to have a favorable long-term clinical outcome.12 Further prospective studies of IL-7 for treatment of PML in patients with ICL are warranted.

**AUTHOR CONTRIBUTIONS**

Dr. Miskin was involved in conceptualization of the study, acquisition of the study drug, analysis and interpretation of the data, and drafting of the manuscript. Dr. Chalkias was involved in analysis and interpretation of the data and critical revision of the manuscript. Dr. Dang was involved in conduction of the experiments. E. Bord was involved in conduction of the experiments. S. Batson was involved in conduction of the experiments. Dr. Koralnik was involved in conceptualization of the study, analysis and interpretation of the data, critical revision, and finalization of the manuscript.

**ACKNOWLEDGMENT**

The authors thank the patient, his family, and the drug manufacturer for giving permission to publish this case.

**STUDY FUNDING**

Supported by NIH grants R01NS 047029 and 074995. The study drug (CYT107) was provided free of charge by the drug manufacturer (RevImmune).

**DISCLOSURE**

D.P. Miskin reports no disclosures. S.G. Chalkias received research support from NIH; X. Dang, E. Bord, and S. Batson report no disclosures. I. J. Koralnik served on the scientific advisory board for Hoffman La Roche, GlaxoSmithKline, Merck Serono, Johnson & Johnson, and Medimmune; serves on the editorial board for *Journal of NeuroVirology* and *Annals of Neurology*; received publishing royalties from UpToDate; has consulted for Bristol Meyers Squibb, Ono Pharmaceuticals, Merck Serono, Hoffman La Roche, GlaxoSmithKline, Perseid Therapeutics, Vertex Pharmaceutical, and Johnson & Johnson; and received research support from Biogen Idec, NIH, and National Multiple Sclerosis Society. Go to *Neurology.org* for full disclosure forms.

Received November 2, 2015. Accepted in final form December 23, 2015.

**REFERENCES**

5. Gheuens S, Bord E, Kesari S, et al. Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of


